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Abstract │ The European Collaborative on Personalised Early Detection and Prevention of Breast 
Cancer (ENVISION) brings together several international research consortia working on different 
aspects of the personalized early detection and prevention of breast cancer. In a consensus 
conference held in 2019, the members of this network identified research areas requiring 
development in order to enable evidence-based personalized interventions that might improve the 
benefits and reduce the harms of existing breast cancer screening and prevention programmes. 
The priority areas identified were: (1) breast cancer subtype-specific risk assessment tools 
applicable to women of all ancestries; (2) intermediate surrogate markers of response to preventive 
measures; (3) novel non-surgical preventive measures to reduce the incidence of breast cancer of 
poor prognosis; and (4) hybrid effectiveness–implementation research combined with modelling 
studies to evaluate the long-term population outcomes of risk-based early detection strategies. The 
implementation of such programmes would require health-care systems to be open to learning and 
adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and 
values, whilst also addressing the ethical and legal issues. In this Consensus Statement, we 
discuss the current state of breast cancer risk prediction, risk-stratified prevention and early 
detection strategies, and their implementation. Throughout, we highlight priorities for advancing 






[H1] Introduction  
Worldwide, breast cancer is the second most commonly diagnosed cancer, with 
approximately 2.1 million new diagnoses and almost 627,000 breast cancer-related deaths 
estimated to have occurred in 2018 1. Breast cancer is a biologically and clinically 
heterogeneous disease, with several recognized histotypes and molecular subtypes that 
have different aetiologies, profiles of risk factors, responses to treatments and prognoses2–
8. In high-income countries, approximately 75% of breast cancers are diagnosed in 
postmenopausal women, although around 5–7% in women younger than 40 years of 
age9,10.  
The risk of developing breast cancer varies among women. Genetic susceptibility, factors 
affecting levels of endogenous hormones (early age at menarche, later age at menopause, 
nulliparity, late age at first birth, having fewer children and shorter durations of 
breastfeeding), exogenous hormone intake (hormonal contraceptive use and hormone 
replacement therapy), lifestyle patterns (high alcohol intake, smoking and physical 
inactivity), anthropometric characteristics (greater weight, weight gain during adulthood and 
higher body fat distribution), a high mammographic breast density, and benign breast 
diseases (non-proliferative disease, proliferative disease without atypia and atypical 
hyperplasia) are all associated with an increased risk of breast cancer11–14. At an individual 
level, the mechanisms and relative contributions of these different risk factors to the 
development of breast cancer and also to particular subtypes of the disease are 
increasingly understood15.  
Women with pathogenic germline mutations in cancer susceptibility genes — that is, in 
BRCA1 or BRCA2 (BRCA1/2) — may opt to undergo prophylactic bilateral mastectomy; 
primary chemoprophylaxis with tamoxifen or other selective oestrogen receptor modulators 
(SERMs) has also been recommended in this group, albeit uptake is low16. Historically, 
members of this high-risk group have been identified on an opportunistic basis following 
self-referral of women with a family history of breast or ovarian cancer, or on the basis of 
an ancestry associated with an increased prevalence of clinically significant pathogenic 
variants of BRCA1/2, for example those of Jewish descent16. Currently, genetic testing 
remains somewhat restricted for women with breast cancer: those with triple-negative, 
bilateral or young-onset disease might be offered a test at diagnosis, but most will be offered 
testing only if they also have a noted family history of the disease16.The 2019 US Preventive 
Services Task Force recommendations expand the population whose eligibility for genetic 
testing should be assessed to include women with a personal or family history of breast, 
ovarian, tubal, or peritoneal cancer in addition to women who have an ancestry associated 
with pathogenic BRCA1/2 variants17.  
At present, the mammographic screening programmes used for early detection of breast 
cancer in most high-income countries are based on the results of trials conducted at least 
20 to 30 years ago18–22, and have age as the only entry criterion, although the starting and 
stopping ages (varying from 40 to 74 years) and the frequency of screens (yearly to 
triennially) differ between countries. This ‘one-size-fits-all’ approach does not take into 
account the heterogeneity of the breast cancer subtypes and of the risk in the population. 
Three decades of mammographic early detection have witnessed an increase in the 
incidence of early stage cancers with a low-risk tumour biology [and an increase in the 
detection of in situ disease, without a concomitant proportionate decrease in incidence of 
advanced-stage disease23,24. Increasingly, calls have been made for a new approach to 
early detection with a focus on the identification of more consequential cancers and on 
avoiding the detection of indolent or ultra-low-risk disease24,25.  
Personalized approaches to the prevention or early detection of breast cancer have 
emerged as highly promising strategies26,27. These programmes require risk assessment of 
each woman in the population, stratification of the population into several risk groups, 
assignment of the individuals to a specific risk group, and tailoring of prevention and early 
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detection interventions to each risk group28 (FIG. 1). Several international research 
consortia (TABLE 1) are studying ways to better understand, estimate and reduce breast 
cancer risk29–32, to use risk-based stratification in order to prevent consequential 
cancers33,34, to evaluate the benefit–harm trade-offs of such strategies35, and to assess the 
acceptability and feasibility of implementing risk-stratified prevention and early detection 
programmes36–38.  
To fulfil the promise of risk-stratified breast cancer prevention and screening, it is important 
not only to generate evidence on the individual component ‘jigsaw pieces’ of prevention and 
early detection programmes, but also to bring these pieces together in a complex adaptive 
system39. The European Collaborative on Personalised Early Detection and Prevention of 
Breast Cancer (ENVISION) comprises leading international research consortia working in 
this specific field (TABLE 1). In 2019, the ENVISION network organized a consensus 
conference to identify research priorities and recommend actions required to enable 
evidence-based risk-stratified prevention and early detection programmes for breast cancer 
(BOX 1; Supplementary Table 1).  
In this Consensus Statement, we review the current knowledge, explore the barriers and 
opportunities, and define key areas for the development and implementation of risk 
assessment, risk-stratified prevention and early detection programmes for breast cancer. 
As representatives of the ENVISION network, we also present herein the recommendations 
formulated at the 2019 consensus conference (BOX 2) in the hope that they stimulate and 
guide such programmes.  
 
[H1] Risk assessment for breast cancer 
[H2] Established risk factors 
Breast cancer risk can be predicted using a combination of common genetic variants, 
mostly single-nucleotide polymorphisms (SNPs); rare coding variants of susceptibility 
genes, including BRCA1/2, PALB2, CHEK2 and ATM; mammographic breast density; 
benign abnormalities in breast biopsy specimens; hormonal, anthropometric and lifestyle 
factors; family history of the disease; and, potentially, epigenetic markers11,13,40–43. Genome-
wide association studies (GWAS) have resulted in the identification of >180 independent 
common genetic variants that together account for ~20% of the familial relative risk of breast 
cancer and ~40% of the heritability attributed to all common variants on genome-wide SNP 
arrays40,41. Each variant confers a small risk, but their effects can be combined into 
polygenic risk scores (PRSs) that are predictive of the risk of developing breast cancer, 
thereby enabling breast cancer risk stratification in the general population44–46.  
The performance of current PRSs have been thoroughly validated in European 
populations44The relative risks associated with individual SNPs and PRS vary between 
breast cancer subtypes, with oestrogen receptor-positive (ER+) disease being more 
strongly predicted than other forms of the disease40,41,44. The current best performing PRS 
is based on 313 SNPs (PRS313): women in the highest 1% of the risk distribution have an 
approximately 4-fold and 3-fold greater risk of developing ER+ and ER− breast cancers, 
respectively, compared with women in the middle quintile (40–60th percentile)44. The risk 
reflected in the PRSs seems to be independent of other established risk factors — that is, 
the effects are approximately multiplicative43. PRS313 provides the highest level of breast 
cancer risk stratification in the population, followed by mammographic breast density and 
the other risk factors45,47.  
Protein-truncating variants (PTVs) in approximately 12 genes are associated with breast 
cancer risk42,48; for some, we know that the strength of association varies between ER+ and 
ER− disease49,50. The risk estimates for variants of some genes are, however, very 
imprecise (see BOX 3). Missense mutations in a subset of these genes have also been 
associated with an increased risk of breast cancer42,51–53. Evidence from in silico and 
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functional studies can help to define this subset of non-truncating variant cancers54–56. 
However, for rare individual variants associated with risk, the level of risk that they impart 
remains uncertain. Most genes tested using commercial multigene panels have not been 
systematically investigated as breast cancer susceptibility genes. The Clinical Genome 
Resource (ClinGen) framework have assessed the strength of evidence between selected 
putative susceptibility genes and breast cancer, and established definitive clinical validity 
classifications for only 10 of 31 genes commonly tested when evaluating breast cancer 
risk57 (BOX 3) 
 
 
[H2] Emerging risk factors 
The epigenome consists of various ‘layers’, including non-coding RNA, histone modification 
and DNA methylation, and has an essential role in establishing the identity and function of 
any given cell by determining which genes remain silent and which are transcribed. A 
plethora of changes in DNA-methylation patterns have been described in breast cancers 
and several of these changes are often also present in the non-malignant breast tissue 
adjacent to the cancer58, supporting the principle that an epigenetic field defect renders 
cells of these tissues susceptible to malignant transformation59. In addition to genetic 
background60,61, a large variety of non-genetic factors, including age62 and endocrine 
disruption63,64 that are known to modulate breast cancer risk also alter patterns of DNA 
methylation. On the basis of these insights, one might speculate that epigenetic profiles 
could predict breast cancer risk.  
To date, several groups have attempted to develop epigenetic risk classifiers for breast 
cancer, but with only modest success, which could be due to several reasons65. First, the 
vast majority of the studies to date used only blood samples for DNA methylation analyses. 
Blood is readily available from participants of several large cohort studies61,66, but breast 
cancer is, by definition, an epithelial disease and hence immune cells in the blood might not 
be an appropriate surrogate tissue for those of the breast. Second, unlike in germline 
genetic analyses, the timing of the sample collection for epigenetic analyses is essential. 
For example, epigenetic analyses using samples obtained from women during cancer 
treatment are likely to produce results that reflect treatment effects and not cancer 
predisposition. Third, unlike PRSs, which are established by combining individual SNPs 
with risk associations that remain statistically significant after multiple test adjustment, 
epigenetic risk signatures are reflective of cell programmes; therefore, approaches that a 
priori select a large number of CpGs for inclusion in the epigenetic signatures are more 
likely to be appropriate. Fourth, the presence of a cancer can modify the epigenome of a 
particular surrogate tissue. For example, a higher granulocyte:lymphocyte ratio is detected 
in the blood of patients with ovarian cancer, which subsequently alters the DNA-methylation 
signature observed when assessing peripheral blood mononuclear cells67. Thus, validation 
of risk-predictive signatures in population-based cohorts is important; however, the majority 
of the existing cohorts do not have appropriate samples available (owing to non-
standardized collection, storage conditions and times, and so on), which makes this 
validation process prone to producing false-negative results.  
Nevertheless, DNA-methylation signatures in easy-to-collect surrogate tissues hold 
promise, not only in advancing risk-prediction strategies, but also, of equal importance, in 
providing novel opportunities to monitor the effects of cancer-preventive measures. In 
addition to epigenetic markers, serum levels of steroid hormones68–70 and a double-strand 
DNA break-repair phenotype71,72  in peripheral blood cells have substantial potential to 





[H2] Risk-prediction models 
Several breast cancer risk-prediction models are available. Empirical models such as the 
Gail model73, the Breast Cancer Surveillance Consortium (BCSC) risk calculator74 and the 
Individualized Coherent Absolute Risk Estimator (iCARE)75–77, do not consider explicit 
genetic models of inheritance and are primarily intended for use in women in the general 
population. By contrast, genetic models such as Tyrer-Cuzick78 and BOADICEA45,79 can, in 
principle, accommodate detailed gamily history information including the exact pedigree 
structure, and information on distant relatives and can, therefore, be applied both at the 
general population level and in women with a strong family history of breast cancer. These 
models all vary in terms of the risk factors considered, the study designs and types of data 
used in their development, and their analytical methods. The validity and clinical utility of 
these risk-assessment tools must be demonstrated before they are implemented routinely 
in the clinical setting80.  
 
[H3] Validity. Analytical validity refers to the accuracy of the test in measuring the underlying 
genotypes (e.g. through gene-panel testing or sequencing for rare mutations), PRSs (e.g. 
through SNP genotyping technologies) and other lifestyle/hormonal risk factors., , which 
may be self-reported or available through electronic health records).  Importantly, the 
analytical validity of comprehensive breast cancer risk-prediction models also depends on 
having reliable relative risk estimates for the effects of the various risk factors; having 
precise  risk estimates of the associations with individual rare and common genetic variants; 
as well as estimates on the joint effects of common genetic variants,the joint effects  of 
common and rare genetic variants, and the combined effects of genetic and other risk 
factors, incliding cancer family history. Clinical vaidity refers to the accuracy of the tool in 
predicting the occurrence of breast cancer.  
Ideally, the individual and combined associations of the various risk factors should be 
derived from large well-designed cohort studies that are representative of the population in 
which the models are intended to be applied. However, cohorts with data that include 
information on all known risk factors are not widely available; therefore, synthetic 
mathematical approaches  have been developed which  combine the risk factors 
distributions from separate cohorts45,75,76. Data generated by the B-CAST29, BRIDGES30, 
BCAC81 and CIMBA82 consortia [Table 1] provide a platform for estimating the individual 
and combined risk factor distributions and breast cancer risk, and have been used in the 
development of the iCARE77 and BOADICEA45 breast cancer risk-predication models. 
Some empirical models, which are commercially available, have been modified to 
incorporate breast cancer PRS, but without accounting for the fact that PRSs explain a 
large fraction of the familial relative risk of breast cancer. The failure to adjust these models 
to account for family history of breast cancer results in substantial levels of miscalibration 
in different risk categories and subsequently compromises the clinical validity of the 
model46.  
Clinical validity Several validation studies assessing  model calibration (that is, the 
agreement between the predicted and the observed risk) or discrimination (the ability of a 
risk score to discriminate between those who will and those who will not develop the 
disease) in large independent cohorts have been published83,84. The interpretation of the 
literature is challenging, however, because these studies have not necessarily assessed 
both model calibration and discrimination in the same sample. Moreover, head-to-head 
comparisons of risk models using the same datasets are lacking. Often the published 
validation studies have used older versions of the risk models without data on all model 
components (in particular, mammographic breast density), have limited sample sizes and 
have varying timescales over which predictions are made, which depend on the number of 
years of follow up in the study. .  
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Ongoing studies by B-CAST29 and BRIDGES30 aim to address these issues by evaluating 
risk-assessment models in multiple prospective cohorts of women initially without breast 
cancer, in diverse settings. Preliminary results indicate that the iCARE77,85 and 
BOADICEA45 models have well calibrated categories of predicted risk and discriminate well 
between women who develop breast cancer from those who do not over 5 to 10-years of 
follow-up84. As such, these models provide valid risk prediction tools that can be used in 
clinical practice.  
 
[H3] Clinical utility. Conceptually, clinical utility refers to the usefulness, benefits and harms 
of an intervention86,87. Clinical utility is a multidimensional construct covering effectiveness 
and cost-effectiveness, as well as the psychosocial, ethical and legal implications of an 
intervention86. Risk assessment per se does not have inherent clinical utility: the 
subsequent adoption of a risk-based intervention based on the results of the assessment 
is what influences the health outcomes88. The use of such a strategy depends on whether 
the risk-based intervention is appropriate, accessible, practicable and acceptable86. The 
interactions of these factors and challenges in assessing them are discussed in more details 
in later sections of this article (FIG. 2).  
 
[H2] Future directions in risk prediction  
We have identified several key areas for development in breast cancer risk modelling 
(BOX 2). These research priorities include models that better predict the risk of specific 
subtypes of breast cancer and with improved risk stratification of women of all ancestries, 
particularly non-European ancestries, who have been understudied.  
Subtyping of breast cancer is currently used routinely in prognostication and treatment, 
although its use in the context of prevention and early detection of the disease is limited. 
The ability to predict susceptibility to the typically more aggressive, ER− forms of breast 
cancer would enable selection of women for enhanced surveillance. Better datasets 
containing both clinical and genetic data are essential to develop and validate models that 
can more accurately predict subtype-specific risk, pathobiological behaviour, and clinical 
outcomes. For example, B-CAST29 and BRIDGES30 are developing such data sources that 
integrate genetic, epidemiological, pathological and clinical data.  
Multi-ancestry GWAS and targeted DNA-sequencing data from individuals of various 
ethnicities will enable translation of PRS-based and gene-based risks to populations of non-
European ancestry. Heritability analyses indicate that breast cancer is a highly polygenic 
disease, with thousands of variants conferring a small effect on risk, and that larger studies 
would result in new discoveries89. The Confluence project89 aims to build a dataset 
comprising >300,000 patients with breast cancer and 300,000 individuals without the 
disease in order to conduct a multi-ancestry GWAS. This study will enable better 
understanding of the aetiology of distinct breast cancer subtypes, more powerful modelling 
of the underlying polygenic risk and improve risk stratification across groups of women with 
different ancestries.  
A large fraction of the unexplained heritability of breast cancer might be attributable to rare 
variants (allele frequency <0.1%) not captured on SNP-arrays90.  
Exome sequencing and replication studies with large cohorts, such as those being 
conducted by BRIDGES30 and PERSPECTIVE I&I36, should be informative in determining 
whether additional susceptibility genes, with risk-defining coding variation, exist. For non-
protein-coding variants, however, much larger whole-genome sequencing datasets, 
coupled with genomic risk prediction, will be required.  
Other promising approaches to improve breast cancer-risk prediction include imaging and 
blood-based biomarkers. Improved use of the mammography or MRI to predict risk is a 
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particularly attractive area of research91–93: parenchymal textual features beyond simple 
mammographic breast density, such as co-occurrence and multi-resolution/spectral 
features, have been shown to be important94, and might be independently predictive of the 
development of breast cancer92,95,96. Screening programmes provide longitudinal data that 
can facilitate studies to identify such imaging biomarkers. Potential blood-based biomarkers 
include microRNAs, tumour-educated platelets and circulating tumour DNA97–99. However, 
these markers might be more suitable for short-term early detection than long-term risk 
prediction  and large longitudinal collections of samples will be required to study them. 
Comprehensive models incorporating genetic and epidemiological risk factors and 
mammographic breast density enable more accurate risk stratification in the general 
population, as well as in carriers of germline pathogenic variants, than is possible with 
models that consider only PRS45,47. Repeat collection of information on the non-genetic risk 
factors at a population level raises further complexities in the logistics of risk assessment. 
The feasibility, clinical utility, costs and cost-effectiveness of risk-based programmes using 
a comprehensive model versus a model with only PRS need to be evaluated. 
To enhance the credibility of a given model and thus confidence in the results, transparency 
(that is, a clear description of the model structure, equations, parameter values and 
assumptions) and validation in relevant settings are essential. The challenge yet lies is 




[H1] Risk-stratified prevention  
In high-income countries that have implemented strategies to prevent or mitigate 
cardiovascular disease (CVD), cancer has superseded CVD to become the most common 
cause of death101. In the context of CVD, clinical parameters indicative of risk (for example, 
blood pressure and serum lipid levels) can be successfully targeted and subsequently used 
to monitor preventive actions102. However, mirroring these concepts in the context of cancer 
has not been possible to date. Cancer development is a multifactorial process that occurs 
at various stages of life and sometimes decades in advance of diagnosis. Avoiding certain 
risk factors for breast cancer (for example, hormone replacement therapy, particularly those 
containing progesterone103), as well as adopting healthier lifestyle patterns (such as limiting 
alcohol consumption104,105 and maintaining a healthy weight106), can have long-term cancer-
preventive effects. Nevertheless, many of the risk factors for breast cancer (including a 
family history of the disease and genetic predisposition, birth weight, age at menarche, age 
at first live birth and age at menopause) are not modifiable, and in many cases the biological 
mechanism underlying the associated increase in breast cancer risk remains unknown. 
Notwithstanding, several active strategies have been shown to modify breast cancer risk. 
 
[H2] Chemoprevention with anti-oestrogens 
The results of prospective randomized controlled trials (RCTs) evaluating primary 
prevention of breast cancer using SERMs or aromatase inhibitors have consistently shown 
a reduced incidence in hormone receptor-positive subtypes of the disease107–119. However, 
in order to prevent one breast cancer in the next 20 years, 22 women needed to take 
tamoxifen daily for 5 years117. The considerable adverse effects of anti-oestrogens and the 
fact that none of these trials have shown any overall survival benefits or a reduction in the 
incidence of aggressive, hormone receptor-negative forms of breast cancer, make it difficult 
to judge whether treating healthy women with these drugs is a more effective strategy than 
reserving them for the adjuvant treatment of only those who actually develop breast cancer. 
Nevertheless, the US Preventive Services Task Force have judged that serious adverse 
effects, such as thrombosis and endometrial cancer, are uncommon and the more common 
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toxicities, such as vasomotor symptoms, are reversible and were only marginally more 
frequent in women on active treatment than in those receiving placebo in the 
aforementioned RCTs120. Accordingly, several international guidelines recommend the use 
of anti-oestrogens as chemopreventives for women at increased risk of breast cancer16,121. 
Whether improved risk stratification would reduce the number of healthy women who need 
to take anti-oestrogens in order to achieve the same preventive effect will need to be 
established in future RCTs.  
 
[H2] Surgical prevention 
Prophylactic bilateral mastectomy is certainly the most effective way of preventing breast 
cancer and reducing breast cancer-specific deaths in the small minority of women with a 
germline pathogenic BRCA1/2 variant122. Nipple-sparing mastectomies are a safe option 
for these women123. General complications include wound dehiscence, infection, implant 
loss or flap necrosis, asymmetry and capsular contracture124. For nipple-sparing 
mastectomies, the overall complication rate has been reported to be 22.3% and the rate of 
nipple necrosis was 5.9%125.  
 
[H2] Other preventative strategies 
In past few years, several new targets of potential preventative interventions for breast 
cancer have been discovered. In particular, progesterone has an essential role in the 
development of aggressive breast cancers. A meta-analysis of 58 studies revealed that 
women receiving a progesterone-containing menopausal hormone therapy not only have a 
higher incidence of breast cancer than women not receiving such therapy or those receiving 
oestrogen-only treatments, but also more cancers that had spread beyond the breast103. 
Furthermore, the data indicated that women receiving progesterone-containing therapy are 
more likely to die from breast cancer than women treated only with oestrogens126. Additional 
evidence for the role of progesterone in breast carcinogenesis comes from the observation 
that women with germline pathogenic BRCA1/2 variants have elevated levels of luteal 
phase progesterone compared with those observed in carriers of non-pathogenic BRCA1/2 
variants127. This increase in progesterone levels leads to an increase in receptor activator 
of nuclear factor-κB ligand (RANKL) levels in the breast128–132, as well as reduced levels of 
the physiological RANKL-antagonist osteoprotegerin128. These effects in turn lead to an and 
expansion of ER− and progesterone receptor (PR)-negative mammary stem cells and 
eventual breast cancer formation133. [In mouse models, BRCA1/2-mediated breast cancer 
formation can be prevented by disrupting the progesterone signalling pathway using the 
competitive PR antagonist mifepristone134. In addition, the findings of a case–control study 
involving women with germline BRCA1/2 mutations indicate that moderate use of dietary 
supplements containing folic acid and vitamin B12 can be protective against BRCA1/2-
associated breast cancer135. Other potential risk-reducing chemotherapeutics include 
aspirin, metformin, statins or other agents136. 
To date, trial evidence for these chemoprevention strategies is lacking. Denosumab, a fully 
humanized antagonistic monoclonal antibody targeting RANKL, has been shown to reduce 
breast epithelial cell proliferation in three premenopausal volunteers133. In postmenopausal 
women with breast cancer, however, denosumab does not seem to alter the incidence of 
contralateral breast cancer137. A prevention study of this agent in carriers of pathogenic 
BRCA1 variants is under way138.  
 
[H2] Future directions in prevention 
Several challenges need to be address in order to advance the field of breast cancer 
prevention. First, drugs that can reduce the incidence of aggressive breast cancers, for 
example, of the triple-negative, HER2+ or luminal B subtypes, need to be identified.  
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Second, the required doses and frequency of administration of these potential preventive 
drugs need to be established. Unlike tamoxifen and aromatase inhibitors, the efficacy and 
safety of which have been tested in many thousands of women in the adjuvant treatment 
setting, no such data exist for the most promising novel preventive drugs (that is, 
progesterone antagonists and denosumab).  
Third, efforts are needed to develop an effective approach to selecting women for whom 
breast cancer primary or secondary prevention measures will provide survival benefits. 
None of the current risk-prediction models intended to identify women at an increased risk 
of developing breast cancer in the absence of a familial predisposition (that is mainly 
carriers of pathogenic BRCA1/2 variants) selectively identify those women at risk of 
developing an aggressive cancer which, if not prevented, would likely lead to death.  
Fourth, surrogate end points are required [Box 2]. Demonstration of a reduction in breast 
cancer-related mortality is recommended before implementation of any early detection 
strategy139, whereas for prevention strategies, robust evidence of a reduced cancer 
incidence seems to be sufficient to recommend clinical implementation140. The focus should 
not, however, be a reduction in the incidence of any breast cancer, but rather of breast 
cancers that hold a poor prognosis. Intermediate surrogate markers are urgently required 
enable timely assessment of the efficacy of potential new breast cancer-preventive 
drugs — particularly in women at high risk of the disease, so as not to substantially delay 
or preclude bilateral mastectomy that is a safe risk-reducing option. A reduction in 
mammographic breast density has proved to be an excellent predictor of response to 
tamoxifen in the preventive setting141. In addition, molecular biomarkers, assessed directly 
in breast tissue and reflective of a field defect58 or indirectly in a surrogate tissue or blood32, 
could potentially provide three essential advantages in prevention strategies for 
premenopausal women  at high risk of breast cancer: (1) they can be measured frequently; 
(2) the dynamics of the molecular biomarkers in individual volunteers might reflect the 
cancer risk in real time, and thus individual adjustments to preventive measures could be 
made ad hoc; and (3), unlike many imaging-based markers, they do not require repeated 
exposure to x-rays (FIG. 3).  
Finally, strategies should be developed to increase the acceptability and accessibility of 
interventions used for breast cancer prevention. Notably, the efficacy of weight loss 
programmes has been shown to be greater amongst individuals who are aware of being at 
high risk of developing breast cancer142. Importantly, weight loss143 and regular 
exercise144,145 not only decrease breast cancer risk, but also the risks of other cancers and 
CVDs. Considering the general health benefits, lifestyle interventions could be 
recommended to women at all levels of breast cancer risk146. Thus, developing effective 
ways to make both lifestyle and chemoprevention options widely available (including within 
screening programmes), acceptable and better understood by health-care professionals 
and the public is essential147 [Box 2].  
 
[H1] Risk-stratified early detection  
The Cancer Control Joint Action European Guide on Quality Improvement in 
Comprehensive Cancer Control148 recommends that the benefits (cancer-specific deaths 
averted and quality-adjusted life years gained), harms (related to false screen findings and 
subsequent investigations, and overdiagnoses and the associated treatments), and cost-
effectiveness of a screening programme should be estimated to guide decisions on 
implementation. RCTs should be used to generate the primary evidence on the 
effectiveness of a new screening programme in reducing cancer-specific mortality148. When 
modifying currently running programmes, however, questions remain regarding what 
constitutes supportive evidence (that is, the required level of evidence and study design)149, 
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and how complete the evidence needs to be before recommendations for implementation 
can be made150.  
 
[H2] Effectiveness 
Two short-term RCTs evaluating the effectiveness of risk-stratified screening for breast 
cancer are currently ongoing: WISDOM in the USA151 and MyPeBS in Europe152. Whilst the 
two trials share a similar design, with intermediate outcome measures (such as stage 
distribution) as end points, their protocols are adapted to the local health-care settings.  
WISDOM151 is a multicentre, pragmatic, adaptive, preference-tolerant RCT comparing risk-
based screening to annual screening in women ages 40 to 74 years. WISDOM is designed 
to determine whether risk-based screening is as safe (the number of stage ≥IIB cancers is 
no more than seen in annual screening) as annual mammographic screening, but with less 
morbidity (measured according to the number of breast biopsies performed) as well as 
greater acceptability, conductivity to preventive interventions and health-care value151. 
Women in the risk-based screening arm are receiving a personal risk assessment based 
on the BCSC risk calculator integrated with a PRS and testing of a panel of nine 
susceptibility genes153. Those women are being stratified into four risk groups: highest risk, 
elevated risk, average risk, and lowest risk. Each group is recommended a screening 
strategy that varies in starting age and the frequency and modality of screening: annual 
mammography with adjunctive MRI, annual mammography, biennial mammography, and 
deferred screening until the age of 50 years (in the lowest risk group comprising women 
aged 40–49 years with 5-year absolute risk <1.3%), respectively154.  
MyPeBS152 is a pragmatic, multicentre RCT that is being performed in five countries 
(Belgium, France, Israel, Italy and the UK) to determine if risk-based screening of women 
aged 40–70 years is non-inferior, in terms of the 4-year incidence of stage ≥II breast cancer, 
to the standard screening programme currently offered in each participating country 
(screening every 2–3 years beginning at 40–50 years of age and ending at 69–74 years of 
age). In MyPeBS, the frequency and modality of screening vary according to the level of 
risk predicted using PRS313 combined with the BCSC74 or the Tyrer–Cuzick78 risk calculator. 
The latter calculator is used only in women with more than one first-degree relative with a 
history of breast or ovarian cancerIn MyPeBS, women are also being classified into four 
risk groups152, although the risk thresholds differ from those used in WISDOM. However, 
the lead investigators of both trials are collecting data in a similar way and have committed 
to pooling the data in order to improve the ability to learn from each study.  
RCTs of screening interventions provide the strongest evidence of efficacy, although they 
have certain limitations. In particular, lifetime health effects cannot be observed in RCTs 
with a limited follow-up duration. Thus, the observed benefit–harm trade-offs might not 
accurately reflect those expected with long-term population screening155. Moreover, the 
outcomes of screening depend on the screening strategy (including the choice of risk-
assessment tool, risk thresholds, screening modalities, screen intervals, and starting and 
stopping ages) and variables relating to the setting (such as the available infrastructure, 
levels of adherence and population preferences)148. Variations in any of these elements can 
alter the benefit–harm trade-offs. Finding the optimum strategy for a given population 
requires comparisons of several alternative screening strategies; however, RCTs are 
inherently limited in their ability to compare more than a few approaches (typically two or 
three 
Simulations using natural history models and decision analysis models provide useful tools 
to study the long-term benefits and harms as well as the cost-effectiveness of various 
screening strategies156–158. Such modelling studies can precede or proceed RCTs of 
screening interventions. Lifetime health effects can be modelled using empirical data, for 
example, from RCTs of different approaches to screening, long-term observational studies 
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and clinical registries159. Modelling studies that incorporate data on the population structure 
and preferences, the natural history and prevalence of disease, life expectancy, the 
available resources and costs can provide an indication of which screening strategies are 
likely to be optimal in a given setting159. Thereafter, the most promising strategies could be 
tested in RCTs. Thus, modelling studies can inform population-screening policies by 
extrapolating evidence beyond the time horizon of prospective trials and enabling the 
translation of evidence from one study population to another.  
 
To date, evidence on the effectiveness of risk-stratified screening has come from model-
based studies26,27,160. Modelling approaches have limitations, however. Models present 
simplified representation of disease progression and intervention outcomes. Moreover, the 
accuracy of the modelling results is dependent on the underlying assumptions and the 
degree of uncertainty in the input parameters161. Estimating overdiagnosis through 
simulations is particularly challenging162, and more so in the absence of data on the rates 




Thus far, few studies have evaluated the cost-effectiveness and benefit–harm trade-offs of 
risk-stratified screening for breast cancer. Vilaprinyo et al.160 risk-stratified women using 
several combinations of risk factors and showed that quinquennial or triennial screening for 
the low-risk or moderate-risk groups and annual screening for the high-risk group, from 50–
74 years of age, would reduce costs, the number of false-positive findings and 
overdiagnosis, whilst averting the same number of deaths as biennial screening between 
the ages of 50 and 69 years. Trentham-Dietz et al.27 used a combination of mammographic 
breast density and four exemplar relative risk levels  for risk-stratification, and showed that 
triennial screening of average-risk women with low breast density, starting at 50 years of 
age, and annual screening of higher-risk women of the same age with high breast density 
would be cost-effective at threshold of $100,000 per quality-adjusted-life years (QALY) 
gained  and would maintain a similar or better balance of benefits and harms than biennial 
screening of average-risk women. Pashayan et al.26 used the distribution of polygenic risk 
in the population combined with other risk factors for stratification and showed that 
compared to screening women from age 50 to 69 years triennially, not screening women at 
lower risk of developing breast cancer would improve the cost-effectiveness and 
benefit:harm ratio of the breast-screening programme.  
 
[H2] Policy implications 
When modifying an existing breast cancer screening programme, several considerations 
need to be taken into account. In particular, agreement should be reached on the framework 
of expected changes and acceptable trade-offs, whether in benefits, harms, net benefit, 
equity, cost or in opportunity cost, in order to facilitate decisions on whether the evidence 
is supportive of the adapted programme. The ultimate aim is to implement risk-stratified 
screening that is justifiable from ethical, legal and societal viewpoints.  
The policy priorities should be explicit: is the priority to maximize the return on investment 
or maximize the benefits of screening? That is, will the total number of screens and/or the 
budget allocated to the screening programme stay the same, but be utilized in a different 
way to maximize the benefits by focusing on higher-risk groups; or will the screening efforts 





[H2] Future directions in early detection 
The key areas are summarized in Box 2. The evidence from modelling studies indicates 
that risk-stratified screening approaches could potentially improve the efficiency and the 
benefit–harm balance of breast cancer screening programmes. Further data is required, 
however, on how the natural course of breast cancer, the sensitivity and specificity of 
mammography, as well as the probability of overdiagnosis vary according to the underlying 
risk of the disease. This information is needed to minimize the assumptions and 
uncertainties in the estimates used in models of risk-tailored screening strategies.  
To have confidence in the validity of the outputs of modelling studies, the models have to 
be well calibrated, the structural assumptions and parameter estimates should be reported 
clearly and explicitly, and the effects of alternative assumptions should be assessed in 
sensitivity analyses100,163–165. Having the code made open-source and easily accessible will 
enhance the transparency of the model157.  
In countries with existing breast cancer screening programmes, randomized health service 
trial designs could be used to evaluate risk-based screening in routine health-care settings. 
Such trials enable the comparison of a new policy or intervention to the current standard 
approach within the context of an existing health service166. Indeed, although modelling, 
routine monitoring and observational studies can provide helpful evidence, they are not a 
replacement for randomized health service studies166.  
Trading-off benefits and harms of different screening strategies is a fundamentally value-
laden activity. Discrete choice experiments (DCEs) provide a quantitative approach to 
eliciting women’s preferences167. In a DCE, participants are asked to choose between a 
series of alternative hypothetical scenarios described in terms of characteristics (or 
attributes) and associated levels.  In making these choices, participants are trading off 
between preferred and less preferred attribute levels presented in each alternative 
scenario. Incorporating the choice probability derived from DCEs for each screening 
approach into decision-analytical modelling might facilitate the identification of optimal 
screening strategies.  
In addition to cost-effectiveness analyses, budget impact analyses will be needed to assess 
the affordability of a risk-stratified screening programme in a given setting168. Finally, 
although risk-stratified screening could potentially reduce overdiagnosis, a major need 
remains for tests that can differentiate, at diagnosis, tumours with progressive potential, in 
order to reduce overtreatment. At present, no test is available for such differentiation at 
diagnosis. However, biomarker-driven decisions regarding adjuvant therapy have been 
incorporated into guidelines for the management of women with certain types of breast 
cancer169, which suggests that such an approach may become viable at diagnosis.    
 
 
[H1] Implementation  
Before risk-stratified prevention and early detection programmes for breast cancer can be 
implemented, health-care providers and policy makers would need to plan the resources, 
build the infrastructure for population-wide risk assessment develop policies and 
regulations to protect the public from stigmatization and discrimination, and provide support 
for informed decision-making of individual women regarding whether to or not participate in 
the screening programme. Ultimately, these actions are needed to ensure the feasibility 
and affordability of providing a high-quality risk-stratified screening programme that is 
accessible to all and is aligned with public values and preferences. There will not be a single 
predefined way of organizing and delivering such programmes. The optimal approach will 
be context specific — to account for the idiosyncrasies of the health-care system, as well 
as the social, economic, cultural and political context (FIG. 4). Here, we are not dealing with 
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a mathematical or technical problem; the implementation of risk-adapted breast cancer 
prevention and screening strategies does not represent a simple change that has a simple 
solution, but rather necessitates complex adaptive changes that require all stakeholders, 
scientists, health-care professionals, the lay public and policy makers to work together.  
 
[H2] Health-care organization readiness 
Organizational readiness for systems change is widely recognized as being necessary for 
the successful implementation of complex changes in health-care settings170. This state 
reflects the extent to which those involved in implementing the new approach are primed, 
motivated and capable of achieving the required changes171. Organizational readiness is a 
dynamic process with pull and push factors between what is possible owing to constant 
emergence of new technological opportunities and what resources are available172.  
To address the challenge of a constantly changing environment, health-care organizations 
should embrace an evolutionary approach rather than espouse sudden dramatic shift, by 
adopting a learning organizational culture and building on existing infrastructure65. In 
keeping with this concept, the adaptive design of WISDOM enables learning and adaptation 
of the risk-assessment model and the screening recommendations accordingly over the 
course of the trial, instead of waiting for certain new discoveries to emerge before starting 
the trial, or excluding participants of non-European ancestry 151The coverage with evidence 
development (CED) model173 is a way of developing a ‘learning-based health-care system’. 
CED provides a mechanism for promising but unproven health technologies to enter 
practice sooner, through time-limited reimbursement that is conditional on a specific 
requirement for generation of further evidence on the performance of the new technology  
Readiness for change requires the commitment and engagement of all stakeholders, 
resources (including knowledge, skills, time, money and infrastructure), and governance170. 
To ensure the commitment of health-care organizations, the need for a change should be 
recognized and embedded in a shared vision, with leadership and coalition of all 
stakeholders170,174. To achieve a shared vision, the stakeholders have to agree on a 
framework of values that are aligned with those of the health-care organization. For 
example, health-care organizations value time-efficiency; therefore, successful 
implementation would require time-respecting strategies and tools, such as having one test 
to predict multiple cancers (which is a goal that FORECEE32 aims to achieve). Overall, 
vision, skills, incentives, resources and action plans are needed to achieve the systems 
change that will be required for implementation of risk-stratified prevention and early 
detection programmes for breast cancer175.  
 
[H2] Stakeholder engagement 
Given the diverse opinions on breast cancer screening amongst key stakeholders at 
present and the specific challenges of risk-stratified screening, engagement of all 
stakeholders is crucial to implementation of new programmes. A stakeholder is a person, 
group or organization involved in or affected by a decision176. Key stakeholders in breast 
cancer prevention and screening include the users and the providers of the service, health-
care professionals, policymakers, payers, advocacy groups, researchers and others. 
Stakeholder engagement would enable the identification of potential misunderstandings 
among the various stakeholders regarding opposition to, and perspectives on, the 
implementation of a risk-stratified programme177. Using a multi-stakeholder approach to 
reach agreement on what would constitute sufficient evidence to change practice and on 
guidelines would increase the chances of implementing the research findings within the 
health-care system151. Such an approach would also help to articulate the wider community 
values and preferences and to build mutual trust, thereby facilitating the implementation of 
a programme that is accessible and acceptable. Stakeholder analysis178 would be useful to 
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not only identify the key stakeholders, but also their interests and influences, and the level 
of involvement of each (whether it be provision of information, consultation, deliberation, 
participatory decision-making or delegated decisions)176.  
 
[H2] Risk communication and its impact 
Many women overestimate their risk of developing breast cancer179 and thus perceive 
screening as ‘almost always a good idea’180. This attitude is attributable to suboptimal levels 
of risk literacy among both patients and doctors as well as the limited transparency in the 
reporting of risks in the media and patient brochures181. Importantly, therefore, women 
should be transparently informed — for example, using fact boxes182,183 — about their 
baseline risks and the benefit:harm ratio of risk-based screening as compared to the 
existing options of a universal screening approach or no screening184. The development of 
risk-stratified programmes will need to include consideration of how to update risk 
assessments as risk-prediction models improve, and how to communicate these changes 
to individuals. 
Communicating information on breast cancer risk alone is unlikely to result in changes in 
health-related behaviours, such as smoking or low levels of physical activity147,185,186. 
Indeed, a methodical review of nine systematic reviews, encompassing at total of 36 unique 
studies, revealed no evidence that providing risk information would have strong, consistent 
or sustained effects on behaviour185. Changes in health-related behaviour can, however, 
be facilitated by including elements of interventions to alter the behaviour in question142.  
Importantly, the available evidence suggests that providing women with their breast cancer 
risk estimates is unlikely to produce elevated distress187. Nevertheless, knowledge of 
whether providing risk estimates will promote informed choices regarding screening 
attendance is lacking, although the evidence base is starting to increase147. More definitive 
conclusions regarding the behavioural and emotional effects of receiving risk estimates 
require studies specifically designed to assess these questions (for example, PROCAS2 37, 
MyPeBS152 and PERSPECTIVE I&I36).  
 
[H2] Acceptability 
Acceptability is a complex and poorly defined concept188. The level of uptake is one index 
of the acceptability of a risk assessment. Many studies have addressed the issue of 
acceptability of risk-stratified screening for breast cancer, from the perspective of 
women38,189 and of health-care professionals and policy makers190. The available evidence 
suggests that risk-stratified screening is broadly acceptable to women if it involves the 
potentially for more frequent screening for those deemed to be high-risk191,192.  
By contrast, a number of concerns exist among professionals working in this area, not least 
regarding costs and the available evidence base38. Similarly, major reservations 
surrounding the appropriateness of reducing the frequency of screening for women deemed 
to be at low risk have been expressed by health-care professionals, policy makers and 
women themselves193. Few high-quality ongoing studies36,37 are examining these issues 
empirically rather than discussing the issues as hypothetical possibilities194. Further 
research is needed to determine the feasibility of risk-stratified screening, particularly 
studies on implementation of screening in a research context, such as PERSPECTIVE I&I36 
and PROCAS2 (REF.37).  
 
[H2] Workforce training  
Effective delivery of risk-stratified prevention and screening services requires health-care 
professionals to be competent in the use of a risk tool, in interpreting and applying the risk 
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scores, and in communicating risk scores effectively to each individual, including discussion 
of the accuracy of the risk prediction and its future implications195. Risk-stratified 
approaches entail (epi)genetic testing for risk assessment. Health-care professionals need 
not become geneticists to effectively use the (epi)genomic information obtained196; 
however, they need to be sufficiently versed in (epi)genomics, for example, in 
understanding the contribution of common and rare coding variants to risk prediction, gene 
panel testing and DNA sequencing modalities, and the implications of identifying 
pathogenic variants with poorly defined cancer risks or genetic variants of uncertain 
significance (VUS)197. Health-care systems should develop clear guidance related to the 
reporting of VUS in order to aid health-care professionals in the management of these 
variants, including descriptions of how patients with VUS should be informed if and when 
variants are found to confer an additional risk.  
To engage with a new prevention and/or early detection scheme, the health-care 
professionals involved need to have a clear understanding of the rationale for risk-
stratification and risk-tailored interventions195, and have adequate knowledge of screening 
risk literacy198 and risk-communication skills; they should also have access to structured 
referral pathways for those women who need more detailed counselling. Accordingly, 
aspects of genomics and risk-stratified interventions should be integrated across the 
continuum of training for health-care professionals, from undergraduate education to broad 
specialty training to continuous professional development programmes. Educational-needs 
assessments should inform the educational requirements of each medical specialty199.  
 
[H2] Ethical, legal and social considerations  
Ethical, legal and social issues need to be considered at every step of implementation of 
risk-based interventions, from health-service planning, invitation of participants and consent 
and sample collection, to risk calculation and communication and storage  of results200,201. 
Some of the issues associated with risk-stratified screening will be dependent on the 
methods by which a programme is implemented201.  
The four principles of bio-ethics promulgated by Beauchamp and Childress202 — autonomy, 
beneficence, non-maleficence and justice — provide a useful framework to understand the 
potential implications of risk-based screening, although these principles are more 
commonly applied to the doctor–patient relationship in the clinical context. Respecting 
autonomy requires that an individual has adequate knowledge and understanding to decide 
upon whether they wish to opt for a given intervention. The capacity of the individual to 
independently make an informed decision will depend on the information content, the 
communication tools used and the adequacy of workforce training in conveying the relevant 
information. Optimizing the balance between providing benefit (beneficence) and the 
potential for harm (maleficence) with a risk-based screening programme requires rigorous 
evaluation. This balance also requires consideration and mitigation of potential unintended 
harms of such programmes. These unintended harms might include the negative 
consequences of risk assessment for individuals (such as anxiety and breaches of 
confidential genetic and other personal data), or at a society level (stigmatization of and 
discrimination against some individuals because of their risk level, and non-participation of 
some individuals in the programme, for example, because they perceive that health care is 
being rationed for those for whom less screening is recommended201). Finally, justice 
relates to the fairness of a programme. Screening programmes have the potential to 
increase health inequalities, owing to differences in the level of uptake between 
socioeconomic groups, including those covered under universal health systems203–205. Risk-
based screening programmes might exacerbate these differences,200 given their additional 
complexity and inherent selectivity relative to universal screening. Efforts are needed to 
mitigate this possibility, for example, through ‘proportionate universalism’206, whereby social 
inequalities are considered and programme resources are targeted commensurately207. 
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Communication relating to screening and risk assessment has to be accessible and 
congruent to the literacy and numeracy level of the recipients while also accurately 
presenting both the potential benefits and risks208. Meeting these requirements will not only 
avoid misinterpretation of the information provided and subsequent inequitable use of 
screening services, but also enable each individual to make an informed decision200. In 
addition, robust legislation is necessary to prevent discrimination and stigmatization, in 
particular, by insurers and employers. Current approaches vary by country, but can be 
broadly divided into four categories: moratoria, industry self-regulation, legal limitations to 
the use of genetic information, and legal bans209,210. As an example, in the UK, an open-
ended Code of practice between insurers and the government exists, prohibiting the use of 
predictive genetic tests except in defined circumstances211.  
 
[H2] Future directions for implementation 
The time is right to perform implementation research in a real-world setting of risk-stratified 
prevention and screening for breast cancer, with clearly defined criteria for success (for 
example, relating to the extent of adoption, appropriateness, acceptability, sustainability, 
cost implications and effectiveness of the programme). The research should be designed 
and conducted together with stakeholder groups, taking into account the ethical, legal and 
social context as well as factors that affect implementation (such as the idiosyncrasies of 
the health-care system and organizational readiness). The process has to be iterative in a 
health-care system conducive to learning and adaptation212.  
To reduce the time lag between obtaining evidence on the effectiveness of a programme 
and its implementation, studies with hybrid effectiveness–implementation design could be 
used213 [Box 2]. WISDOM151 and MyPeBS152 are examples of studies with hybrid designs 
primarily focused on effectiveness whilst also exploring the ‘implementability’ of the 
intervention. Several strategies adopted in WISDOM, such as the adaptive design, multi-
stakeholder approach214 and CED model173, will accelerate the implementation of the 
findings. By contrast, PERSPECTIVE I&I36 has a hybrid design focused primarily on 
implementation outcomes (including the acceptability and feasibility of risk-based 
screening, uptake of genetic testing for risk assessment and screening behaviours); 
however, data on effectiveness (that is, screening outcomes of different risk groups) are 
also being collected, and simulation modelling is being performed to assess the efficiency, 
resource-use, costs and cost-effectiveness of risk-based screening at a population-level 
using real-world administrative data. A third type of hybrid design involves the simultaneous 
study of effectiveness and implementation strategies. This approach enables the 
demonstration of which implementation strategies work in a given context, as opposed to 
demonstrating the effects of a particular implementation strategy on the adoption or uptake 
of an intervention213.  
The model of evidence-generating health care could be adopted to study the clinical utility 
of risk stratification in the prevention of breast cancer among carriers of pathogenic 
BRCA1/2 variants. This approach would require linking of genetic profiles and the outcomes 
of preventive interventions to cancer registries, training of treating physicians to develop a 
working knowledge of cancer risk and genetics, and the development of decision aids for 
patients.  
Women with a family history of breast cancer constitute a high-impact group in which to first 
pilot national level application of integrated breast cancer risk assessment. The results of 






[H1] Conclusions  
Substantial progress has been made in research focused on estimating an individual 
woman’s risk of developing breast cancer, applying risk stratification in breast cancer 
prevention studies, modelling the benefit–harm balance of risk-stratified early detection 
approaches, and assessing the acceptability and feasibility of implementing risk-based 
prevention and screening programmes. To translate this progress into improvements in 
population health outcomes, a systems approach to the evaluation of risk-based 
programmes is necessary, taking into account the health-care organization’s readiness for 
change, its openness to learning and adapting, the social context and the need for 
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Table 1 │Consortia participating in the ENVISION network  
Acronym Consortium Description and/or aims of the consortium  Funder  Ref. 
B-CAST Breast Cancer 
Stratification  
 Define the influence of risk factors, including reproductive 
history, lifestyle, mammographic breast density and 
germline genetic variation, on susceptibility to breast cancer 
overall and for disease subtypes characterized by clinical 
and molecular markers  
 Define the influence of risk factors and tumour subtypes on 
clinical prognosis. 
 Develop, validate and implement breast cancer risk and 
prognostication models for breast cancer, overall and for 
different subtypes. 
 Raise awareness. That is, promote the development and 
integration of personalized breast cancer prevention within 
national public health programmes. 
EU Horizon 2020  29 
BCAC Breast Cancer 
Association Consortium  
 International consortium of collaborative groups that share 
data from multiple studies in breast cancer.  
 Identify genes that might be relevant to the risk of breast 
cancer. 





BRCA-ERC Understanding cancer 
development in BRCA1/2 
pathogenic variant 
carriers for improved 
Early detection and Risk 
Control 
 
 Understand cell non-autonomous factors in carriers of 
BRCA1 or BRCA2 pathogenic variants that contribute to 
cancer development. 
 Use cell-free DNA methylation-based markers for early 
detection of ovarian cancer. 
 Develop new strategies and intermediate surrogate end 




BRIDGES Breast Cancer Risk After 
Diagnostic Gene 
Sequencing  
 Identify breast cancer susceptibility genes. 
 Estimate risks associated with different genetic variants and 
incorporate into the BOADICEA risk prediction model to 
provide individualized risk estimates. 
 Implement individualized risk prediction in clinical settings. 
EU Horizon 2020 30 
EU-TOPIA Towards Improved 
Screening for Breast, 
Cervical and colorectal 
Cancer in All of Europe 
 Develop and validate microsimulation models of breast, 
cervical and colorectal cancer screening in countries across 
Europe to assess current screening programmes. 
 To assess inequalities in and barriers to uptake of screening 
 To develop road-maps to improve existing screening 
programmes in Europe. 
EU Horizon 2020 35 
FORECEE Female Cancer 
Prediction Using Cervical 
Omics to Individualise 
Screening and 
Prevention  
 Utilize data on the cervical epigenome, genome and 
microbiome to develop personalized early detection and 
prevention strategies for breast, ovarian, endometrial and 
cervical cancer. 
 Assess the ethical, health-economic, legal and societal 
aspects of using epigenetic markers for risk prediction. 
 Develop strategies for communicating cancer risk. 
EU Horizon 2020 32 
MyPeBS My Personalised Breast 
Screening  
 Multi-country randomized trial of personalized breast 
cancer screening comparing risk-based screening to 
standard screening offered in each participating country 
among women aged 40 to 70 years: US National Library of 
Medicine. ClinicalTrials.gov, 
https://clinicaltrials.gov/ct2/show/NCT03672331 (2020 
YEAR of most recent update).]  
 Assess if individual risk-based screening is non-inferior or 
superior to the current standard of care in terms of 
reduction of the incidence of stage II or higher breast 
cancer.  





Prevention and Early 
detection of Breast 
cancer: Integration & 
Implementation 
 Identification and validation of novel moderate to high risk 
breast cancer susceptibility genes  
 Improvement, validation and adaptation of a web-based tool 
for comprehensive breast cancer-risk prediction that is 
suitable for the Canadian context.  
Canadian Institutes 








 Development of a framework to support implementation of 
a personalized risk-based approach to breast cancer 
screening within existing mammography centres.  
 Economic analyses for optimal personalized risk-based 
screening implementation.  
Breast Cancer 
Foundation 
PROCAS2 Predicting Risk of Cancer 
at Screening  
 Assess the feasibility of individualized risk assessment 
during screening appointments. 
 Assess the impact of implementing personalized risk 
assessment on women, health-care staff and related 
organizations.  
NIHR UK 37 
WISDOM Women Informed to 
Screen Depending on 
Measures of Risk 
 Multicentre, pragmatic, adaptive, preference-tolerant 
randomized controlled trial comparing risk-based screening 
to annual screening of women aged 40 to 74 years   
https://clinicaltrials.gov/ct2/show/NCT02620852 
(2020 year of most recent update). 
 Determine if personalized breast cancer screening will lead 
to fewer harms, improve breast cancer prevention and be 









Fig. 1 │ A schematic outlining a personalized approach to early detection and 
prevention of breast cancer. Women entering a personalized early detection programme 
would initially be assessed using a validated tool to determine their estimated risk of breast 
cancer. Subsequently, the women would be stratified into appropriate risk groups, such that 
they can receive tailored interventions. This approach might mean that some women start 
mammographic screening at a younger age, have different screening intervals or have 
supplemental screening with another imaging modality, such as MRI. Women deemed to 
be at higher risk of breast cancer could, in addition, be offered prophylactic treatment. A 
healthy lifestyle would be recommended to all women, independent of risk level.  
 
Fig. 2 │ Risk-stratified early detection and prevention programmes as complex 
adaptive systems. Various questions will define the risk-stratified programme, including 
which risk factors to include risk assessments, what risk threshold to use for risk 
stratification, how many risk groups to have, when to do risk assessments, how often to 
screen and to whom screening should be offered. Decision-making regarding these 
questions will be influenced by the research evidence, the available resources, the health-
care setting, and societal values, preferences and social norms. The choices made in 
addressing each of these questions will determine whether the programme will be effective 
in reducing cancer-specific death and improving benefit–harm balance of screening, and 
be cost-effective, acceptable, accessible and feasible to implement. Dynamic interactions 
exist between each of these factors, and thus a change in one factor affects all others. 
Hence, the importance of holistic, ‘systems thinking’ approach.  
 
Fig. 3 │ Overview of personalized risk reduction and breast cancer prevention 
paradigms. Various risk factors contribute to field defects in breast tissues that favour the 
development of breast cancer. The presence of such field defects can be assessed using 
biomarkers and/or imaging in order to guide personalized prevention strategies, the 
success of which can be monitored on an ongoing basis through intermediate surrogates 
(for example, reduction or resolution of the field defect) that reflect the ultimate goal of a 
decreased incidence of breast cancers with features indicative of a poor prognosis.  
 
Fig. 4 │ Implementation of risk-stratified early detection and prevention programmes 
in a learning health-care system. The schematic illustrates the various multi-level 
interactions between the different components needed for the implementation of risk-
stratified programmes for the early detection and prevention of cancer. The ultimate goal is 
an improvement in population health outcomes. To achieve this goal, the process has to be 





Box 1 │ Process of developing the recommendations of the ENVISION network 
The ENVISION network meeting was attended by 119 delegates from 19 countries: 14 
countries in Europe (Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Italy, 
Netherlands, Slovenia, Spain, Switzerland, Sweden and UK) as well as Israel, USA, 
Canada, Malaysia, and Australia. Together, the delegates brought diverse expertise in risk-
based breast cancer research and health services (epidemiology, statistics, genetics, 
epigenetics, oncology, clinical genetics, pathology, gynaecology, radiology, surgery, 
primary care, public health, psychology, ethics, health economics, policy, screening 
services and health-care management), with representatives from academia, health-care 
organizations, industry politics and non-profit organizations (Europa Donna and the 
Association of European Cancer League).  
The meeting was held over three days. During the first day, presentations covered 
the latest evidence (‘where we are now’) relating to breast cancer risk prediction, risk-
stratification for prevention, risk-stratification for early detection at the population level and 
the implementation of such strategies. Each presentation was followed by a discussion 
session for the delegates to identify gaps in research (‘where do we want to be’). During 
the second day, through six workshops (focused on risk assessment, early detection, 
prevention, engaging stakeholders, health-care organization readiness, and ethical, legal 
and social implications (ELSI)), the delegates explored how to meet these gaps (‘how do 
we get where we want to be’). During the third day, named delegates, in coordination with 
the presenters, discussants and the facilitators of the workshops, presented 
recommendation for each of the 18 areas covered in the ENVISION meeting (genetic risk, 
epigenetic risk, classical risk factors, risk prediction, breast cancer subtypes, imaging, 
diagnostic tools for early detection, prevention, specific considerations in high risk women, 
outcome, trial logistics, implementation, economic evaluation, communication and decision 
aids, policy landscape, ELSI, workforce training, and health-care organization readiness). 
The presentation of each recommendation was followed by discussion and checking 
consensus.  
Each delegate who contributed through presenting the evidence, the workshop 
discussions and the recommendations presented a written summary. After collating these 





Box 2 │ Summary of the key recommendations of the ENVISION  
Assessment of breast cancer risk  
 Risk-assessment tools should be validated using prospective cohorts in the context in 
which they will be used and for each population ancestry. 
 Risk-assessment tools that enable better predictions of breast cancer subtype-specific 
risk and risk in women of non-European descent need to be developed and validated. 
 Discovery research to identify additional genetic variants and new markers is required in 
order to improve risk-stratification. 
 The trade-off between the accuracy of comprehensive models and their usability at 
population level should be evaluated. 
 Algorithm transparency should be ensured, with explicit reporting of the assumptions 
made.  
 
Breast cancer prevention  
 Develop ways to better select high-risk women predisposed to breast cancer of poor 
prognosis.  
 Clinically relevant surrogate markers (reflecting the field defect in breast tissues) that 
provide early indications of the effectiveness of the preventive measures in reducing 
incidence of breast cancer of poor prognosis need to be identified.  
 Programmes should incorporate healthy lifestyle recommendations for women at all risk 
levels. 
 Prevention-specific drug doses, schemes and schedules need to be defined, and 
rational drug repositioning strategies should be explored. 
 Better and early assessment of the acceptability of new preventive interventions is 
required. 
 
Risk-stratified early detection 
 Discovery research is required to identify and validated early detection markers that can 
differentiate progressive from non-progressive breast cancers.  
 Develop risk-stratified early detection strategies underpinned by understanding of how 
the natural course of breast cancer, sensitivity of the test (for example, mammography) 
and the probability of overdiagnosis vary according to risk levels. 
 Optimize variables related to risk assessment (which risk factors to include, what age to 
start screening, how often to screen, and so on) and risk stratification (how many risk 
groups to specify and the risk threshold for each group), thus resulting in a cost-effective, 
feasible, acceptable and equitably accessible early detection programme. 
 Modelling studies can be used to inform on long-term population outcomes and the 
optimal design of risk-stratified early detection programmes. 
 Pragmatic randomized study designs, such as randomized health service studies, 
should be used to generate evidence on the effectiveness of risk-stratified early 
detection approaches in a given setting.  
 
Programme implementation  
 Adopt hybrid effectiveness–implementation research designs to reduce the time lag 




 Shift away from small studies with hypothetical scenarios performed in silos to 
multidisciplinary research with engagement of all stakeholders in order to ensure a 
systems approach to implementation studies in real-world settings.  
 A framework for learning health-care system should be adopted.  
 The implementation process in a given setting needs to be aligned with health-care 
organization readiness for change and the social values, preferences and norms.  
 The best ways of communicating risk and supporting behavioural changes in response 




Box 3 | Genes for which rare variants have been associated with breast cancer  
Gene PTV 
associated 
with BC risk? 
Missense variants 
associated with BC 
risk? 
Relative Risk 
for PTV (90% CI) 
ClinGen 
evidence 
ATM Yes Yes 2.8 (2.2–3.7) Definitive 
BARD1  Unknown 2.1 (1.5-3.0)48  Definitive 
BRCA1 Yes Yes 11.4 Definitive 
BRCA2 Yes Yes 11.7 Definitive 
CDH1 Yes Unknown 6.6 (2.2–19.9) Definitive 
CHEK2 Yes Yes 3.0 (2.6–3.5) Definitive 
NBN Yes Unknown 2.7 (1.9–3.7) Limited 
NF1 Yes Unknown 2.6 (2.1–3.2) Not evaluated 
PALB2 Yes Unknown 5.3 (3.0–9.4) Definitive 
PTEN Yes Yes 8.8 (2.7-34.4)48  Definitive 
RAD51D  Unknown 2.1 (1.2-3.72)48  Limited 
STK11 Yes Unknown No reliable 
estimate 
Definitive 
TP53 Yes Yes 105 (62–165) Definitive 
 
Sources: Easton et al.42 and Lee et al.57 Risk estimates from Easton et al.42, except where 
indicated otherwise. Note that risk estimates calculated by LaDuca et al.48 come with 95% 
CI and are derived from a study of individuals referred for testing and may not be unbiased 
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• Do the figures convey the intended message?
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Supplementary Table 1 │ Participants of the European Conference on Risk-Stratified Prevention and 
Early Detection of Breast Cancer, Hall in Tirol, Austria, 26––28 June 2019 [Au: Would it be possible to 
add a column indicating the specialization/expertise of each delegate?]  
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